全球肝素市場規模、佔有率、成長分析，依給藥途徑（靜脈注射和皮下）、最終用途（門診和住院）- 2024-2031 年產業預測

Global Heparin Market Size, Share, Growth Analysis, By Route of Administration(Intravenous and Subcutaneous), By End Use(Outpatient and Inpatient) - Industry Forecast 2024-2031

出版日期: 2024年04月10日 | 出版商:

SkyQuest | 英文 219 Pages | 商品交期: 3-5個工作天內

價格

簡介目錄

2022年全球肝素市場規模為74.8億美元，預計將從2023年的76.8億美元成長到2031年的95.1億美元，預測期內（2024-2031年）複合年成長率為2.7%。

2022 年 8 月，FDA 批准了 Momenta Pharmaceuticals, Inc. 的 M-Enoxaparin 藥物。 Momenta 和諾華的學名藥子公司 Sandoz 正在開發 M-Enoxaparin，這是一種技術更先進的 Lovenox 學名藥。它也在主要的骨科手術中進行，例如膝關節和髖關節置換術。肝素研究的最新進展旨在生產用於化療的超低分子量肝素，為肝素業務創造了新的成長潛力。許多疾病和病症，包括深部靜脈栓塞、肺栓塞、急性冠狀動脈症候群、心房顫動、體外循環和心臟手術後的血液濾過，都需要肝素治療。該設備可用於主要的骨科手術，包括膝關節和髖關節置換術。由於心血管疾病等潛在因素，靜脈血栓形成的頻率正在增加，這推動了全球市場的成長。由於接受心臟和骨科手術的患者數量不斷增加，以及這些類型的手術中肝素的使用不斷增加，市場正在擴大。然而，各種不利的肝素副作用，例如肝素引起的血小板減少症，限制了市場的成長能力。肝素來自動物，這一事實引起了人們對可用性和安全性的嚴重擔憂，這是另一個限制因素。

市場概況
北美洲
- 美國
- 加拿大
歐洲
- 德國
- 西班牙
- 法國
- 英國
- 歐洲其他地區
亞太地區
- 中國
- 印度
- 日本
- 韓國
- 亞太其他地區
拉丁美洲
- 巴西
- 拉丁美洲其他地區
中東和非洲 (MEA)
- 海灣合作理事會國家
- 南非
- MEA 的其餘部分

競爭格局

前 5 名玩家比較
2021 年關鍵參與者的市場定位
主要市場參與者所採取的策略
最佳制勝策略
近期市集活動
主要公司市佔率（%），2021年

主要公司簡介

Pfizer Inc. (United States)
Sanofi SA (France)
Leo Pharma A/S (Denmark)
Fresenius Kabi AG (Germany)
Aspen Holdings (South Africa)
Teva Pharmaceutical Industries Ltd. (Israel)
Dr. Reddy's Laboratories Ltd. (India)
B. Braun Melsungen AG (Germany)
LEO Pharma A/S (Denmark)
Baxter International Inc. (United States)
Shanghai Institute of Biological Products (China)
Nanjing King-friend Biochemical Pharmaceutical (China)
Changzhou Qianhong Bio-pharma (China)
Opocrin SpA (Italy)
Nantong Pharmaceutical (China)
Celsus Laboratories Inc. (United States)
Hebei Changshan Biochemical Pharmaceutical (China)
Bioiberica SAU (Spain)
Dongying Tiandong Pharmaceutical (China)
Shenzhen Hepalink Pharmaceutical Co., Ltd. (China)
Pharma Action GmbH (Germany)

簡介目錄

Product Code: SQMIG35H2166

Global Heparin Market size was valued at USD 7.48 billion in 2022 and is poised to grow from USD 7.68 billion in 2023 to USD 9.51 billion by 2031, at a CAGR of 2.7% during the forecast period (2024-2031).

August 2022 saw the FDA approve Momenta Pharmaceuticals, Inc.'s M-Enoxaparin medicine. Momenta and Sandoz, Novartis AG's generics subsidiary, are developing M-Enoxaparin, a more technologically advanced generic version of lovenox. It is also administered during major orthopedic surgeries like as knee and hip replacements. Recent advancements in heparin research, which aim to manufacture ultra-low molecular weight heparin for use in chemotherapy, have created fresh growth potential for the heparin business. Many illnesses and conditions, including deep vein thrombosis, pulmonary embolism, acute coronary syndrome, atrial fibrillation, cardiopulmonary bypass, and hemofiltration after heart surgery, are treated with heparin. This device can be utilized for major orthopedic procedures, including knee and hip replacements. The frequency of venous thrombosis is increasing due to underlying factors such as cardiovascular sickness, which is driving the global market's growth. The market is expanding due to the rising number of patients undergoing cardiac and orthopaedic surgeries, as well as the growing usage of heparin in these types of surgeries. However, a variety of unfavorable heparin side effects, such as thrombocytopenia brought on by heparin, limit the market's ability to grow. The fact that heparin is derived from animal sources, which raises significant concerns about availability and safety, is another constraining factor.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Heparin Market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Heparin Market Segmental Analysis

The type, mode of administration, source, end use, and region of the global heparin market are the segments that make up this market. The market is divided into three types: unfractionated, extremely low weight, and low molecular weight. The market is divided into inpatient and outpatient segments based on end use. The market is divided into intravenous and subcutaneous segments based on the mode of administration. The market is divided into bovine, porcine, and other sources according to source. The market is divided into Latin America, Middle East and Africa, Asia Pacific, North America, and Europe.

Drivers of the Global Heparin Market

Venous thromboembolism, or VTE, is more frequent in the elderly but can affect anyone at any age. Heart failure is one of the many illnesses that older individuals are more likely to suffer from than younger people. Heart failure can result in thrombosis. Congestive heart failure is far more common in the elderly, with 85% of heart failure patients being over 65. Atrial fibrillation is three times as common in adults over 80 than in those under 65. These events increase the risk of pulmonary embolism, particularly in older adults. As a result, the requirement for heparin to treat illnesses grows along with the number of elderly individuals, driving up demand for heparin.

Restraints in the Global Heparin Market

The adverse effects of heparin are the primary barriers to market expansion. Bleeding is the most common side effect of heparin. Heparin may cause spontaneous bleeding from the mouth, gums, uterus, stomach, intestines, and open surgical wounds. Heparin may also result in heparin-induced thrombocytopenia (HIT), which increases the risk of bleeding by stimulating the production of antibodies by the immune system against the body's platelets. Therefore, during the forecast period, market expansion may be constrained by the adverse effects of heparin.

Market Trends of the Global Heparin Market

Effective reversal medications are becoming more and more necessary to counteract the anticoagulant effects of heparin and other anticoagulant therapies during surgery or emergency scenarios. In order to give the heparin market another growth path, research and development is now being done on novel anticoagulant reversal medicines.

Executive Summary

Market Overview
Wheel of Fortune

Research Methodology

Information Procurement
Secondary & Primary Data Sources
Market Size Estimation
Market Assumptions & Limitations

Parent Market Analysis

Market Overview
Market Size
Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges

Key Market Insights

Technology Analysis
Pricing Analysis
Supply Chain Analysis
Value Chain Analysis
Ecosystem of the Market
IP Analysis
Trade Analysis
Startup Analysis
Raw Material Analysis
Innovation Matrix
Pipeline Product Analysis
Macroeconomic Indicators
Top Investment Analysis
Key Success Factor
Degree of Competition

Market Dynamics & Outlook

Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges
Regulatory Landscape
Porters Analysis
- Competitive rivalry
- Threat of Substitute Products
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers
Skyquest Special Insights on Future Disruptions
- Political Impact
- Economic Impact
- Social Impact
- Technical Impact
- Environmental Impact
- Legal Impact

Global Heparin Market by Route of Administration

Market Overview
Intravenous and Subcutaneous

Global Heparin Market by End Use

Market Overview
Outpatient and Inpatient

Global Heparin Market Size by Region

Market Overview
North America
- USA
- Canada
Europe
- Germany
- Spain
- France
- UK
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America
- Brazil
- Rest of Latin America
Middle East & Africa (MEA)
- GCC Countries
- South Africa
- Rest of MEA

Competitive Landscape

Top 5 Player Comparison
Market Positioning of Key Players, 2021
Strategies Adopted by Key Market Players
Top Winning Strategies
- By Development
- By Company
- By Year
Recent Activities in the Market
Key Companies Market Share (%), 2021

Key Company Profiles

Pfizer Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sanofi S.A. (France)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Leo Pharma A/S (Denmark)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Fresenius Kabi AG (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Aspen Holdings (South Africa)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Teva Pharmaceutical Industries Ltd. (Israel)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Dr. Reddy's Laboratories Ltd. (India)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
B. Braun Melsungen AG (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
LEO Pharma A/S (Denmark)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Baxter International Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Shanghai Institute of Biological Products (China)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Nanjing King-friend Biochemical Pharmaceutical (China)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Changzhou Qianhong Bio-pharma (China)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Opocrin S.p.A. (Italy)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Nantong Pharmaceutical (China)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Celsus Laboratories Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Hebei Changshan Biochemical Pharmaceutical (China)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bioiberica S.A.U. (Spain)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Dongying Tiandong Pharmaceutical (China)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Shenzhen Hepalink Pharmaceutical Co., Ltd. (China)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Pharma Action GmbH (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments